Literature DB >> 1815962

The effect of verapamil on cardiac sympathetic function.

E C Meyer1, D K Sommers, J C Avenant.   

Abstract

We have used systolic time intervals (STI) to measure inotrophy and chronotropy as indirect measures of the actions of noradrenaline, in order to ascertain whether the depletion of cardiac noradrenaline stores which has been shown to occur in laboratory rats after chronic verapamil treatment could be demonstrated in healthy volunteers. Placebo, verapamil, or atenolol were given by slow intravenous injection to 8 healthy volunteers and QS2I, LVETI, and PEP/LVET were measured. Verapamil pretreatment resulted in a positive inotropic state. Intravenous verapamil after oral pretreatment caused accentuated negative inotropic and chronotropic responses as compared with acute verapamil without pretreatment. We postulate that the observed initial inotropic effect may be in part due to an increase in the amount of noradrenaline available to the myocardium intrasynaptically, and that the accentuated negative response after intravenous or oral verapamil may result from a decrease in cardiac noradrenaline storage.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815962     DOI: 10.1007/BF00314977

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  LEFT VENTRICULAR EJECTION TIME INDEX IN MAN.

Authors:  A M WEISSLER; L C HARRIS; G D WHITE
Journal:  J Appl Physiol       Date:  1963-09       Impact factor: 3.531

2.  A critical review of the systolic time intervals.

Authors:  R P Lewis; S E Rittogers; W F Froester; H Boudoulas
Journal:  Circulation       Date:  1977-08       Impact factor: 29.690

3.  Effect of chronic verapamil therapy on cardiac norepinephrine and beta-adrenoceptor density.

Authors:  W G Nayler; J S Dillon; W J Sturrock; D J Buckley
Journal:  J Cardiovasc Pharmacol       Date:  1988-12       Impact factor: 3.105

4.  Influence of amyl nitrite inhalation on the systolic time intervals in normal subjects and in patients with ischemic heart disease.

Authors:  T Sawayama; M Ochiai; S Marumoto; T Matsuura; I Niki
Journal:  Circulation       Date:  1969-09       Impact factor: 29.690

5.  Inhibition of high affinity synaptosomal uptake systems by verapamil.

Authors:  R McGee; J E Schneider
Journal:  Mol Pharmacol       Date:  1979-11       Impact factor: 4.436

6.  The interaction of calcium antagonists (slow channel blockers) with myocardial alpha adrenoceptors.

Authors:  W G Nayler; J E Thompson; B Jarrott
Journal:  J Mol Cell Cardiol       Date:  1982-03       Impact factor: 5.000

7.  A reserpine-like action of verapamil on cardiac sympathetic nerves.

Authors:  A Chaudhry; M M Vohra
Journal:  Eur J Pharmacol       Date:  1984-01-13       Impact factor: 4.432

Review 8.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

Review 9.  Usefulness of systolic time intervals in coronary artery disease.

Authors:  R P Lewis; H Boudoulas; T G Welch; W F Forester
Journal:  Am J Cardiol       Date:  1976-04       Impact factor: 2.778

10.  The effect of steady-state increases in systemic arterial pressure on the duration of left ventricular ejection time.

Authors:  J A Shaver; F W Kroetz; J J Leonard; H W Paley
Journal:  J Clin Invest       Date:  1968-01       Impact factor: 14.808

View more
  1 in total

1.  Contrasting effects of verapamil and amlodipine on cardiovascular stress responses in hypertension.

Authors:  J D Lefrandt; J Heitmann; K Sevre; M Castellano; M Hausberg; M Fallon; A Urbigkeit; M Rostrup; E Agabiti-Rosei; K H Rahn; M Murphy; F Zannad; P J de Kam; A J Smit
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.